-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35

Benzinga·10/28/2026 17:18:15
Listen to the news
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.